Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-0853-2020

Drug recall · February 26, 2020

Glycopyrrolate Injection recall

Why: Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.

Lots / codes

Lot #CGP190001-A, Exp. 07/31/2020

Quantity
4600 Vials
Company
AuroMedics Pharma LLC, East Windsor, NJ
Distribution
Ohio, Louisiana, Mississippi
Initiated
February 7, 2020 · Voluntary: Firm initiated
Classified
February 20, 2020
Reported
February 26, 2020
Ended
March 8, 2023
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.